TaiMed and AcedrA officially signed an exclusive license, commercialization  and distribution agreement for Trogarzo in the Middle East and North Africa  region.
AcedrA shall pursue regulatory approvals, promote and commercialize  the Product.  AcedrA will supply Trogarzo in the region through a Named  Patient Supply where local regulations will allow until regulatory  approvals are obtained. AcedrA Pharmaceutical Company (also known as AcedrA  BioPharmaceuticals) is a specialized company dedicated in operating in unmet medical & commercial needs for contributing to the patient care  covering the region of the Middle East & Africa from the Kingdom of Saudi  Arabia. AcedrA is a Saudi company based in the capital Al Riyadh with  offices in United Arab Emirates, Dubai and Tunisia, Tunis; focused on  Marketing & Distribution of Pharmaceuticals & Biotechnology of Niche  Therapeutic Segments Novel Portfolios: Rare Diseases, Orphan Drugs,  Hematology, Oncology, Metabolic Diseases, Genetic Disorders, Enzyme  Replacement Therapies, Recombinant Technologies, Life-Threatening  Conditions Medicines, Neurology, Biosimilars, etc.

This agreement grants exclusivity to Acedra for the following MENA   countries: Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Bahrain,  Oman, Jordan, Egypt, Lebanon, Iraq, Libya, Tunisia, Algeria, Morocco,   and Sudan.

Trogarzo is currently primarily sold in the United States. However, the company and Acedra officially signed an exclusive license, commercialization and distribution agreement for Trogarzo in the Middle East and North Africa  region. This agreement is expected to expand the user base of Trogarzo,  consequently increasing the company's future revenue and positively  impacting the overall interests and long-term value.

The company looks to expand its global reach so more patients can access  Trogarzo. TaiMed and AcedrA will work together to enable healthcare  providers to access Trogarzo for people living with MDR HIV who meet the  eligibility criteria.